Paul J. Clancy - 11 Jun 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Reporting relationship: Director
Issuer ticker: XLO
Reported as of: 11 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2025, 16:36:08 UTC
Prior SEC filing: 12 Jun 2025
Next SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Kevin Brennan, Attorney-in-Fact

Key filing fact

Paul J. Clancy filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 12 Jun 2025.

Key facts

This page summarizes Paul J. Clancy's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2025, 16:36.

Change

Previous filing in this sequence was filed on 12 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001409601 Primary reporting owner

Clancy Paul J

Relationship: Director
Address: 828 WINTER STREET, SUITE 300, WALTHAM
Signature: /s/ Kevin Brennan, Attorney-in-Fact
Signature date: 12 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XLO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +31,000
Change %
Price: $0.000000
Shares after: 31,000
Date: 11 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,000
Exercise price: $0.6930
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC remarks

Exhibit 24 - Power of Attorney